RNase-Fc Fusion Protein RSLV-132

**Semantic type:** Pharmacologic Substance

**Definition:** A fusion protein composed of a full-length, catalytically active human ribonuclease (RNase) moiety fused to the amino-terminus of an engineered human immunoglobulin G1 (IgG1) Fc domain, with potential anti-inflammatory and immunomodulatory activities. Upon administration, RNase-Fc fusion protein RSLV-132 catalyzes the degradation of extracellular RNA circulating in the blood and removes them from the blood circulation. This may prevent the presentation of RNA autoantigens to the immune system and reduce inflammation. Circulating RNA-containing autoantigens and autoantibodies drive chronic inflammation in autoimmune diseases such as lupus and Sjogren's syndrome. Both viral RNA and RNA-containing autoantibodies in the blood circulation may be associated with inflammation in post-acute sequelae of SARS-CoV-2 infection (PASC) or long COVID.

**Synonyms:** - RSLV 132 - RSLV-132 - RSLV-132 - RSLV132